Type to search

Health Care News

J.P. Morgan will advise NeuroRx

Avatar photo
Share

WILMINGTON– NeuroRx, a Wilmington clinical stage biopharma company developing the first drug regimen to treat severe bipolar depression, has retained J.P. Morgan as financial advisor.

NeuroRx will begin enrolling patients shortly in a Phase 2b/3 pivotal study targeting severe bipolar depression in patients with acute suicidal ideation and behavior. The FDA awarded fast track designation to the drug regimen in August.

The FDA awarded FAST TRACK designation to this investigational drug regimen in August, 2017.

There currently is no approved drug therapy for bipolar depression in patients with acute suicidal ideation and behavior. The only FDA-approved treatment is electroconvulsive therapy.

Get the free DBT email newsletter  

Follow the people, companies and issues that matter most to business in Delaware.

Tags:

You Might also Like

Leave a Comment

Your email address will not be published. Required fields are marked *

Premier Digital Partners

© 2022 Delaware Business Times

Holiday flash sale! Subscribe to Delaware Business Times and save 50%.

Limited time offer. New subscribers only.

Holiday flash sale!

Subscribe to Delaware Business Times and save 50%

Limited time offer. New subscribers only.